ICOS mutants
AssigneeMayo Foundation for Medical Education and Research
InventorsLieping Chen, Jurgen Bajorath
Life of this patent
Estimating the term…
Abstract
Purified ICOS polypeptides are described, as well as nucleic acids encoding the polypeptides, vectors including the nucleic acids, host cells containing the vectors, and methods for using the polypeptides, nucleic acids, and host cells.
Claims23
A purified ICOS polypeptide having altered affinity for B7-H2 compared to a wild-type ICOS polypeptide, wherein said affinity is at least 6% of the affinity of said wild-type ICOS polypeptide.
A method for inhibiting T cell activation, comprising contacting an antigen-presenting cell with a purified ICOS polypeptide, wherein said polypeptide is capable of binding to B7-H2 with increased affinity relative to a wild-type ICOS polypeptide having the amino acid sequence of SEQ ID NO:
- 12.
Dependencies are inferred from the claim text.